DUBLIN, Ireland — Endo International plc has announced executive changes in its U.S. branded drug and research-and-development units.
Endo said Patrick Barry has been appointed as senior vice president of U.S. branded pharmaceuticals effective immediately and Matthew Davis as senior vice president of R&D for branded pharmaceuticals effective Jan. 3.
Barry, who comes to Endo from Sanofi, will have responsibility for all commercial activities for U.S. branded pharmaceuticals, including strategy, new product planning, marketing and sales. Davis, who rejoins Endo from Lupin Pharmaceuticals Inc., will lead R&D activities for U.S. branded pharmaceuticals.
“We are excited to have Patrick and Matthew join Endo and I look forward to working closely with them,” stated Paul Campanelli, Endo president and chief executive officer of Endo. “They bring to Endo significant experience and demonstrated track records of success in their respective areas of expertise. Importantly, both are proven leaders and have built and inspired strong teams that have consistently exceeded performance expectations. We look forward to their success at Endo.”
Barry had worked at Sanofi for over two decades, holding roles of increasing responsibility in such areas as sales leadership, commercial operations, marketing, launch planning, and training and leadership development. Most recently, he served as general manager and head of North America general medicines at Sanfoi. Prior to that, he was vice president and head of U.S. specialty at the company.
“I’m pleased to have joined Endo at such a pivotal time and look forward to maximizing the potential of our people, specialty assets and established brands to drive growth,” Barry commented.
Before returning to Endo, Davis was chief medical officer at Lupin and previously at URL Pharma, where he spearheaded five NDA approvals and received 21 U.S. patents. Endo noted that his expertise spans drug development, device development and lifecycle management across such therapeutic areas as aesthetics, dermatology, neurology, oncology and rheumatology. He also has held R&D leadership roles at other pharmaceutical companies, directing clinical development, clinical operations, medical affairs, and pharmacovigilance.
“I began my career nearly 20 years ago at Endo on the team that aided in the development, helped to gain approval and launch Lidoderm,” Davis stated. “I couldn’t be more thrilled to be back at the company to utilize my collective experience and lead the branded R&D team.”
Endo also said that, with its significant organizational restructuring, U.S. branded pharmaceuticals president Joseph Ciaffoni is leaving the company. In addition, Susan Hall, executive vice president, chief scientific officer and global head of R&D is slated to leave the company on March 31. In the interim, she will assist with the transition and as serve as an adviser and, after her departure, provide consultative services in connection with the development of Xiaflex for cellulite.
Under Endo’s new unified operating model, global supply chain, manufacturing, global quality and R&D support both the branded and generic drug businesses and report to Terrance Coughlin, executive vice president and chief operating officer.
Last week, Endo also had announced the appointment of Blaise Coleman as executive vice president and chief financial officer. Coleman has been serving as interim CFO since Nov. 22.